Royal Philips announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Liver Fat Quantification tools as part of the latest release of its ultrasound systems EPIQ Elite and Affiniti, bringing the cost and accessibility advantages of sonography to the diagnosis of early-stage liver disease. Featured at this year?s Radiological Society of North America (RSNA) annual meeting (November 23 ? December 2, Chicago, USA), the new tools will allow clinicians to track liver health. With the extended remote functionality of Collaboration Live on both the EPIQ and Affiniti platforms, technicians can also securely access on-demand, real-time guidance and decision support to enhance diagnostic confidence and workflow efficiency during exams. Philips Ultrasound Systems EPIQ and Affiniti on Release 9.0 now support radiologists and hepatologists in the diagnosis and treatment from early-stage to advanced liver disease, making it easier to perform longitudinal studies to assess liver disease progression. With this latest release, the company further strengthens its liver solution and expands its full availability to the Affiniti 70 and Affiniti 50 ? supported by the innovative PureWave C5-1 Curved transducer, now also available on Affiniti 50 ? to enhance diagnostic confidence in abdominal, hepatology, and vascular and gynaecological ultrasound exams as well. The new Liver Fat Quantification tools complement the company?s existing ultimate solution for liver assessment with real-time shear wave imaging, contrast enhanced ultrasound (CEUS) and fusion and navigation. The Liver Fat Quantification tools, which feature ease of use plus intuitive workflow and reporting, is available on both the C5-1 and the small footprint mC7-2 MicroConvex transducer, to accommodate different body types, from smaller patients to high BMI patients. Philips will debut its Liver Fat Quantification solution at the Radiological Society of North America (RSNA) Annual Meeting later this month.